Mehdi Javanbakht1, Ali Keshtkaran2, Hossien Shabaninejad3,4, Hassan Karami2, Maryam Zakerinia5, Sajad Delavari6. 1. Health Economics Research Unit, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK. 2. Health Economics Department, School of Management and Information Sciences, Shiraz University of Medical Sciences, Shiraz, Iran. 3. Department of Health Services Management, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran. 4. Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran. 5. Department of Internal Medicine, BMT Unit, Hematology Research Center, and Organ Transplant Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran. 6. Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Abstract
BACKGROUND: β-Thalassemia is a prevalent genetic disease in Mediterranean countries. The most common treatments for this disease are blood transfusion plus iron chelation (BTIC) therapy and bone marrow transplantation (BMT). Patients using these procedures experience different health-related quality of life (HRQoL). The purpose of the present study was to measure HRQoL in these patients using 2 different multiattribute quality of life (QoL) scales. METHODS: In this cross-sectional study, data were gathered using 3 instruments: a socio-demographic questionnaire, EQ-5D, and SF-36. A total of 196 patients with β-thalassemia were randomly selected from 2 hospitals in Shiraz (Southern Iran). Data were analyzed using logistic regression and multiple regression models to identify factors that affect the patients' HRQoL. RESULTS: The average EQ-5D index and EQ visual analog scale (VAS) scores were 0.86 (95% CI: 0.83-0.89) and 71.85 (95% CI: 69.13-74.58), respectively. Patients with BMT reported significantly higher EQ VAS scores (83.27 vs 68.55, respectively). The results showed that patients who lived in rural area and patients with BMT reported higher EQ VAS scores (rural; β= 10.25, P = .006 and BMT; β= 11.88, P = .000). As well, SF-36 between 2 groups of patients were statistically significant in physical component scale (PCS). CONCLUSION: Patients in the BMT group experienced higher HRQoL in both physical and mental aspects compared to those in the BTIC group. More studies are needed to assess the relative cost-effectiveness of these methods in developing countries.
BACKGROUND: β-Thalassemia is a prevalent genetic disease in Mediterranean countries. The most common treatments for this disease are blood transfusion plus iron chelation (BTIC) therapy and bone marrow transplantation (BMT). Patients using these procedures experience different health-related quality of life (HRQoL). The purpose of the present study was to measure HRQoL in these patients using 2 different multiattribute quality of life (QoL) scales. METHODS: In this cross-sectional study, data were gathered using 3 instruments: a socio-demographic questionnaire, EQ-5D, and SF-36. A total of 196 patients with β-thalassemia were randomly selected from 2 hospitals in Shiraz (Southern Iran). Data were analyzed using logistic regression and multiple regression models to identify factors that affect the patients' HRQoL. RESULTS: The average EQ-5D index and EQ visual analog scale (VAS) scores were 0.86 (95% CI: 0.83-0.89) and 71.85 (95% CI: 69.13-74.58), respectively. Patients with BMT reported significantly higher EQ VAS scores (83.27 vs 68.55, respectively). The results showed that patients who lived in rural area and patients with BMT reported higher EQ VAS scores (rural; β= 10.25, P = .006 and BMT; β= 11.88, P = .000). As well, SF-36 between 2 groups of patients were statistically significant in physical component scale (PCS). CONCLUSION:Patients in the BMT group experienced higher HRQoL in both physical and mental aspects compared to those in the BTIC group. More studies are needed to assess the relative cost-effectiveness of these methods in developing countries.
Authors: C A Uyl-de Groot; I Buijt; I J M Gloudemans; G J Ossenkoppele; H P Berg; P C Huijgens Journal: Eur J Haematol Date: 2005-02 Impact factor: 2.997
Authors: A Sobota; R Yamashita; Y Xu; F Trachtenberg; P Kohlbry; D A Kleinert; P J Giardina; J L Kwiatkowski; D Foote; V Thayalasuthan; J B Porter; A A Thompson; L Schilling; C T Quinn; E J Neufeld Journal: Am J Hematol Date: 2011-01 Impact factor: 10.047
Authors: D K L Cheuk; A S P Mok; A C W Lee; A K S Chiang; S Y Ha; Y L Lau; G C F Chan Journal: Bone Marrow Transplant Date: 2008-06-16 Impact factor: 5.483
Authors: Sarah E Lawson; Irene A G Roberts; Persis Amrolia; Inderjeet Dokal; Richard Szydlo; Philip J Darbyshire Journal: Br J Haematol Date: 2003-01 Impact factor: 6.998
Authors: G Caocci; A Vacca; E Piras; V Serreli; C Dessi; M Marcias; P Risso; G La Nasa Journal: Bone Marrow Transplant Date: 2016-09-19 Impact factor: 5.483
Authors: Farrukh Shah; Paul Telfer; Mark Velangi; Shivan Pancham; Robert Wynn; Sally Pollard; Elizabeth Chalmers; Jonathan Kell; Angela M Carter; Joe Hickey; Clark Paramore; Minesh Jobanputra; Kate Ryan Journal: EJHaem Date: 2021-09-08